Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03215108
Other study ID # 2017-03-098-001
Secondary ID
Status Recruiting
Phase N/A
First received May 26, 2017
Last updated July 9, 2017
Start date July 12, 2017
Est. completion date December 31, 2019

Study information

Verified date May 2017
Source Samsung Medical Center
Contact Jong Kyun Lee, MD PhD
Phone +82-2-3410-3409
Email jongk.lee@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered self-expandable metal stent (C-CSEMS).


Description:

Covered self-expandable metal stent (C-CSEMS) has the risk of obstruction of the cystic duct, and the main and branch pancreatic ducts due to strong radial force and covering material, which results in cholecystitis and pancreatitis.

A flower-type covered self-expandable metal stent (F-CSEMS) having a five-petal-shaped design with side grooves was constructed to prevent the obstruction of the cystic duct orifice.

This study investigated the value of the F-CSEMS in protection for cholecystitis and pancreatitis.

The investigators will enroll patients with distal MBO (Malignant Biliary Obstruction) who received placement at the Samsung Medical Center. Transpapillary flower-type covered self-expandable metal stent (F-CSEMS) placements will be included in this study.

The diagnosis of MBO will be based on imaging and/or pathological findings. Malignancy was proved by histopathological confirmation obtained by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA), bile duct biopsy (cytology), pancreatic duct cytology, or liver biopsy.

The investigators will evaluate the frequency of pancreatitis and cholecystitis.

Furthermore, the investigators will evaluate various parameters to clarify the predictive factors of pancreatitis and cholecystitis. The following 10 variables will be evaluated in pancreatitis by univariate analysis: [1] sex, [2] age, [3] primary disease, [4] Covered type (partially or fully), [5] SEMS with high AF, [6] F-CSEMS with high RF, [7] EST before F-CSEMS, [8] previous biliary stent, [9] contrast injection into the pancreatic duct (pancreatogram), and [10] the position of the distal stent edge.

The following 11 variables will be evaluated in cholecystitis by univariate analysis: [1] sex, [2] age, [3] regions of stricture, [4] F-CSEMS with high AF AF (axial force), [5] F-CSEMS with high RF, [6] previous biliary stent, [7] gallbladder stone, [8] contrast injection into the gallbladder (GB injection), [9] involvement to the orifice of the cystic duct (OCD), [10] position of distal stent edge, and [11] cystic duct occlusion by F-CSEMS.

software: nQuery + nTerim (version 4.0)

- One-sided Chi-square test for proportion comparison

H0: p1=p2 vs H1: p1>p2 (The incidence of complications in the flower-type covered stent is smaller than in the conventional stent.)

p1 = incident rate of complication in full covered stent group p2 = incident rate of complication in flower-type covered stent group

- Set p1(incident rate of complication in full covered stent group) = 15% = 0.15

- expected % decrement in incidence rate = 40%, 50%, 60%, 70% --> p2 = 0.09, 0.075, 0.06, 0.045

- Significance level (alpha) = 0.05

- Maximum number of patients who can be enrolled = 10 per month at SMC = 120 per year

- Expected enroll period = 1 year = 12 months

1. Sample size calculation with targeted power of 80% Expected % decrement in incidence rate 70% p2 4.5% Required n per group 116 Required total sample size 232 Required enroll period (year) 1.9

2. Power calculation with a total sample size of 232 (116 per group) Expected % decrement in incidence rate 40% 50% 60% 70% p2 9.0% 7.5% 6.0% 4.5% Expected power (%) 32 48 64 80

3. Minimum % decrement to be detected with power of 80% Planned enroll period (year) 1 1.5 2 2.5 3 Enroll-able n per group 60 90 120 150 180 Enroll-able total sample size 120 180 240 300 360 Minimum % decrement to be detected 93.33% 78.70% 68.70% 62.70% 58.00% Expected p2 1.0% 3.2% 4.7% 5.6% 6.3%


Recruitment information / eligibility

Status Recruiting
Enrollment 256
Est. completion date December 31, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers No
Gender All
Age group 19 Years to 85 Years
Eligibility Inclusion Criteria:

- Adults from 19 to 85 years of age who have voluntarily agreed to the clinical trial and signed a written agreement

- Patients with malignant extrahepatic bile duct obstruction without surgery

Exclusion Criteria:

- Patients who had already undergone surgical biliary drainage

- Patients who previously underwent percutaneous spinal cholecystectomy (PTGBD)

- Patients who underwent conventional metal-on-metal self-expandable metal stents (C-CSEMS)

- Patients who underwent biliary plastic stent implantation for more than 15 days

- Patients with malignant stricture of the intrahepatic bile duct and patients with stenosis within 2 cm of the liver

- Patients whose expected life expectancy is less than 3 months

- Pregnant patient

- Patients who can not undergo endoscopic procedures based on the judgment of the researcher

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Endoscopic Retrograde CholangioPancreatography(ERCP)
This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).

Locations

Country Name City State
Korea, Republic of SamsungMC Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pancreatitis, Cholecystitis - Occurrence rate : % The incidence of pancreatitis is calculated using percentiles. 3 months after procedure
Primary Pancreatitis, Cholecystitis - Severity The extent of each side effect is described in the Adverse Reactions Report according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) Rating System version 4.0. 3 months after procedure
Secondary Stent-related adverse events Post -ERCP pancreatitis, Severity of pancreatitis, Bleeding, Microperforation 6 months after procedure
Secondary Stent patency We followed up the stent patency until the time of patient death or stent occlusion. 6 months after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04941924 - The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction. N/A
Active, not recruiting NCT03672019 - A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
Recruiting NCT05220475 - A Comparison of a Fully Covered Self-expandable Metal Stent With an External Anchoring Plastic Stent and Uncovered Stent N/A
Completed NCT02001779 - IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Not yet recruiting NCT06375954 - EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) N/A
Recruiting NCT05786326 - Multihole Fully Covered Metallic Stents in the Management of Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Completed NCT01869894 - A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction N/A
Not yet recruiting NCT05804201 - EUS-guided Hepatico-gastrostomy With Hot Giobor N/A
Recruiting NCT01686425 - Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage N/A
Recruiting NCT04898777 - EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction N/A
Recruiting NCT05169398 - EUS-guided Hepatico-gastrostomy Using a Novel Lumen Apposing Metal Stent N/A
Enrolling by invitation NCT05233293 - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma N/A
Completed NCT03812250 - EUS-guided Biliary Drainage vs. ERCP Assisted Transpapillary Drainage for Malignant Biliary Obstruction N/A
Completed NCT03000855 - EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures Phase 2/Phase 3
Recruiting NCT01073514 - Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction N/A
Recruiting NCT05142839 - Palliation of Gastric Outflow Obstruction in Case of Concomitant Biliary Obstruction. N/A
Recruiting NCT05729867 - Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC N/A
Completed NCT04405752 - Evaluation of a New Metal Biliary Stent of 12-mm Diameter: a Case Control Study